載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$29.36
−US$1.16 · -3.80%
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
前收盤價
US$29.36
−US$1.16 · -3.80%
盤中時間採用ET。市場資料可能有所延遲。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日內區間
目前US$29.36
52週區間
目前US$29.36
盤中時間採用ET。市場資料可能有所延遲。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日內區間
目前US$29.36
52週區間
目前US$29.36
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.72億 USD | 2億 USD | 1.3億 USD | 8859.5萬 USD | 7247.6萬 USD |
| 銷貨成本 | 6793.4萬 USD | 4924.5萬 USD | 3964萬 USD | 2538.3萬 USD | 1821.4萬 USD |
| 毛利 | 2.04億 USD | 1.5億 USD | 9055.3萬 USD | 6321.2萬 USD | 5426.2萬 USD |
| 研究與開發 | 1284.6萬 USD | 1223萬 USD | 665.2萬 USD | 305萬 USD | 1108.4萬 USD |
| 銷售、一般及管理費用 | 1.53億 USD | — | — | — | 3981.5萬 USD |
| 營業費用 | 1.66億 USD | 1.42億 USD | 9012.2萬 USD | 6129.3萬 USD | 5264.8萬 USD |
| 利息支出 | 2418萬 USD | 2278.6萬 USD | 2132.4萬 USD | 724.4萬 USD | 543.6萬 USD |
| 折舊和攤銷 | 1967.7萬 USD | 1453.7萬 USD | 1234萬 USD | 366.5萬 USD | 239.6萬 USD |
| 營業利益 | 3860.9萬 USD | 882.2萬 USD | 43.1萬 USD | 191.9萬 USD | 161.4萬 USD |
| 淨利 | −513.9萬 USD | −1748.1萬 USD | −2441.1萬 USD | −1408.6萬 USD | −1800.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$66.50
上漲空間 126.50%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2013年2月8日 | 1:5 | — | — |
股票分割 | 2012年2月24日 | 1:8 | — | — |
股票分割 | 2007年9月28日 | 231:500 | — | — |
已生效 2013年2月8日
1:5
已生效 2012年2月24日
1:8
已生效 2007年9月28日
231:500
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3696.33萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2596.75萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1422.45萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO907.94萬0.07%139.17億 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS838.2萬0.02%338.69億 USD0.31%US$78.35+0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH762.27萬1.65%4.62億 USD0.35%US$64.65+1.60%
Vanguard Russell 2000 ETFVTWO686.52萬0.04%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM565.88萬0.09%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
